Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En sikkerhet og effektivitetsstudie som evaluerer CTX001 hos personer med alvorlig sigdcellesykdom

21. august 2026 oppdatert av: Vertex Pharmaceuticals Incorporated

En fase 1/2/3-studie for å evaluere sikkerheten og effekten av en enkelt dose autolog CRISPR-Cas9 modifisert CD34+ humane hematopoietiske stam- og stamceller (CTX001) hos personer med alvorlig sigdcellesykdom

Dette er en enkelt-arm, åpen, multi-site, enkeltdose fase 1/2/3 studie i personer med alvorlig sigdcellesykdom (SCD). Studien vil evaluere sikkerheten og effekten av autologe CRISPR-Cas9 modifiserte CD34+ humane hematopoietiske stam- og stamceller (hHSPCs) ved bruk av CTX001.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

63

Fase

  • Fase 2
  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Brussels, Belgia
        • Hopital Universitaire des Enfants Reine Fabiola (HUDERF)
      • Toronto, Canada
        • The Hospital for Sick Children
    • California
      • Palo Alto, California, Forente stater, 94304
        • Lucile Packard Children's Hospital of Stanford University
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Ann & Robert Lurie Children's Hospital of Chicago
      • Chicago, Illinois, Forente stater, 60612
        • University of Illinois at Chicago Hospitals and Health Systems
    • New York
      • New York, New York, Forente stater, 10032
        • Columbia University Medical Center (21+ years)
      • New York, New York, Forente stater, 10032
        • Columbia University Medical Center (≤21 years)
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38105
        • St. Jude Children's Research Hospital
      • Nashville, Tennessee, Forente stater, 37203
        • The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
    • Texas
      • San Antonio, Texas, Forente stater, 78229
        • Methodist Children's Hospital/Texas Transplant Institute
      • Paris, Frankrike
        • Hôpital Necker Enfants malades
      • Rome, Italia
        • Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS
      • London, Storbritannia
        • Imperial College Healthcare NHS Trust, Hammersmith Hospital
      • London, Storbritannia
        • Royal London and St Bartholomew's Hospital, Pathology and Pharmacy Building
      • Düsseldorf, Tyskland
        • University Hospital Duesseldorf
      • Regensburg, Tyskland
        • Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine, Paediatric Haemotology, Oncology and Stem Cell Transplantation

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 35 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Beskrivelse

Viktige inkluderingskriterier:

  • Diagnose av alvorlig sigdcellesykdom som definert av:
  • Dokumentert genotype for alvorlig sigdcellesykdom
  • Historie med minst to alvorlige vaso-okklusive krisehendelser per år de siste to årene før innmelding
  • Kvalifisert for autolog stamcelletransplantasjon i henhold til etterforskernes vurdering

Nøkkelekskluderingskriterier:

  • En tilgjengelig 10/10 humant leukocyttantigen (HLA)-matchet relatert donor
  • Tidligere hematopoetisk stamcelletransplantasjon (HSCT)
  • Klinisk signifikant og aktiv bakteriell, viral, sopp- eller parasittisk infeksjon

Andre protokolldefinerte inklusjons-/ekskluderingskriterier kan gjelde

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Exa-cel
Exa-cel (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants received a single infusion of exa-cel through a central venous catheter on Day 1.
Administered by IV infusion following myeloablative conditioning with busulfan.
Andre navn:
  • Exagamglogen autotemcel
  • CTX001

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
A VOC is a condition of SCD characterized by vaso-occlusion presenting as recurrent pain episodes. The percentage of participants who remain VOC free after achieving VF12 were data reported in the outcome measure.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants Who Achieve Neutrophil Engraftment
Tidsramme: Up to 24 months post exa-cel infusion.
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, within 42 days after exa-cel infusion without the use of unmodified CD34+ cells after reaching the nadir, defined as ANC <500/µL.
Up to 24 months post exa-cel infusion.
Time to Neutrophil Engraftment for Participants Who Achieve Neutrophil Engraftment
Tidsramme: Up to 24 months post exa-cel infusion.
Neutrophil engraftment is defined as the first day of 3 consecutive measurements of absolute neutrophil count (ANC)≥500/μL on 3 different days, without use of the unmodified CD34+ cells after reaching the nadir, defined as ANC<500/μL. Time to neutrophil engraftment was calculated by the neutrophil engraftment date subtract exa-cel infusion date +1.
Up to 24 months post exa-cel infusion.
Time to Platelet Engraftment for Participants Who Achieve Platelet Engraftment
Tidsramme: From Exa-cel infusion up to 2 years after exa-cel infusion
Platelet engraftment is defined as the first day of 3 consecutive measurements of unsupported (no platelet transfusions for the last 7 days) platelet ≥50,000/μL on 3 different days after Exa-cel infusion. For participants discharged early day 7 after the last platelet transfusion will be the day of platelet engraftment, as long as 3 subsequent and consecutive unsupported measurements on 3 different days are >50,000/μL. For participants who have been discharged prior to platelet engraftment, it is recommended to collect blood every 2 to 3 days to obtain an accurate assessment of platelet engraftment. Time to platelet engraftment was defined as first of 3 consecutive measurements on 3 different days with platelet ≥50 × 109/L without a platelet transfusion for 7 consecutive days.
From Exa-cel infusion up to 2 years after exa-cel infusion
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: From receiving exa-cel infusion up to 2 years
From receiving exa-cel infusion up to 2 years
Transplant-related Mortality (TRM) Within 100 Days After Exa-cel Infusion
Tidsramme: Within 100 days after exa-cel infusion
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM participants who have died within 100 days, or with at least 100 days post exa-cel infusion.
Within 100 days after exa-cel infusion
Transplant-related Mortality Within 12 Months Post Exa-cel Infusion
Tidsramme: Within 12 months post exa-cel infusion
The transplant-related mortality is defined as death related to Busulfan and/or exa-cel infusion. The number and proportion of TRM within 12 months will be summarized for participants who have died within 12 months, or with at least 12 months post exa-cel infusion.
Within 12 months post exa-cel infusion
All-cause Mortality
Tidsramme: From exa-cel infusion up to 2 years
All-cause mortality from exa-cel infusion up to 2 years
From exa-cel infusion up to 2 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants Free From Inpatient Hospitalization for Severe VOCs Sustained for at Least 12 Months (HF12)
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The VF12 defines absence of any severe vaso-occlusive crises (VOCs) for at least 12 consecutive months after exa-cel infusion. Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs were included in the analysis. Relative reduction from baseline was calculated as 100 % × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 90% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 90% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 80% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 80% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 75% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 75% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With at Least 50% Relative Reduction From Baseline in Annualized Rate of Severe VOCs for Participants Who do Not Achieve VF12 up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of participants with at least 50% relative reduction from baseline was reported. The percentages were calculated relative to the number of participants who did not achieve VF12.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Duration of Severe VOC Free in Participant Who Have Achieved VF12
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The VF12 means the absence of any severe VOC for at least 12 consecutive months after exa-cel infusion. The evaluation of the severe VOC free duration in participants who achieved VF12 started 60 days after the last RBC transfusion for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Rate of Inpatient Hospitalizations for Severe VOCs Up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Relative Reduction From Baseline in Annualized Duration of Hospitalization for Severe VOCs Who Did Not Achieve HF12 Up to 24 Months After Exa-cel Infusion
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion

The HF12 means Free from inpatient hospitalization for severe vaso-occlusive crises (VOCs) and sustained for at least 12 months after exa-cel infusion. Relative reduction from baseline is calculated as 100% × (Baseline value - post-baseline value) / Baseline value. Annualized rate is calculated by the Total number of events/number of years.

Only severe VOCs adjudicated by an outcome measure adjudication committee as meeting the protocol definition of severe VOCs are included in the analysis.

From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained Fetal Hemoglobin (HbF) Greater Than or Equal to (≥) 20% for at Least 3 Months
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained HbF ≥ 20% for at Least 6 Months
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Percentage of Participants With Sustained HbF ≥20% for at Least 12 Months
Tidsramme: From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
The HbF evaluation started 60 days after the last RBC transfusion for post transplant support or SCD management. The last RBC transfusion refers to that in the period of the initial RBC transfusions for post transplant support or SCD management.
From 60 days after last RBC transfusion up to 2 years after exa-cel infusion
Number of Annualized Red Blood Cells (RBC) Units Transfused After Exa-cel Infusion
Tidsramme: 2 years after exa-cel infusion
The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
2 years after exa-cel infusion
Participants With Relative Reduction From Baseline in Number of Annualized Units of Red Blood Cells Transfused
Tidsramme: 2 years after exa-cel infusion
Relative reduction from baseline = 100% × (Baseline value - post baseline value)/Baseline value. The evaluation of the number of annualized RBC units transfused after exa-cel infusion started 12 months after exa-cel infusion.
2 years after exa-cel infusion
Total Fetal Hemoglobin (HbF) Concentration Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Total Hemoglobin (Hb) Concentration Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change From Baseline in Reticulocyte Count Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change From Baseline in Indirect Bilirubin Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Participants With Detectable Haptoglobin Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Participants With Lactate Dehydrogenase (LDH) Level <300 Units Per Liter (U/L) Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Alleles With Intended Genetic Modification Present in Peripheral Blood Leukocytes Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Percentage of Alleles With Intended Genetic Modification Present in CD34+ Cells of Bone Marrow Over Time
Tidsramme: 2 years after exa-cel infusion
2 years after exa-cel infusion
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥12 and <18 Years of Age
Tidsramme: 2 years after exa-cel infusion
The 11-point pain numerical rating scale (NRS) is used to measures pain intensity on a 1-dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
2 years after exa-cel infusion
Change in Patient-reported Outcome (PRO) Over Time Assessed Using on a 11-point Numerical Rating Scale [NRS]) for Participants ≥18 and ≤35 Years of Age
Tidsramme: 2 years after exa-cel infusion
The 11 point pain numerical rating scale (NRS) is used to measures pain intensity on a 1 dimensional score ranging from 0 (no pain) to 10 (worst possible pain).
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-Y)Visual Analogue Scale (VAS) for Participants ≥12 and <18 Years of Age
Tidsramme: 2 years after exa-cel infusion
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using EuroQol Quality of Life Scale (EQ-5D-5L) for Participants ≥18 and ≤35 Years of Age
Tidsramme: 2 years after exa-cel infusion
The EQ-5D VAS is a version of the EQ-5D designed for children and adolescents S). The EQ VAS records the subject's self-rated health on a 100-point VAS scale that ranged from 0 (worst imaginable health) to 100 (best imaginable health) points.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Functional Assessment of Cancer Therapy-bone Marrow Transplant (FACT-BMT) Score for Participants ≥18 and ≤35 Years of Age
Tidsramme: 2 years after exa-cel infusion
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant scale (FACT-BMT) is a quality of life instrument that assesses the effects of bone marrow transplantation (BMT) on a patient's physical, social/family, emotional, and functional well-being while taking into consideration BMT-specific concerns. The assessment has different questions, each scored on a Likert scale from 0-4. The overall score is computed by adding scores of the questions and falls in the range 0-148, with higher scores indicating higher levels of overall well-being.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Score on Different Domains for Participants ≥18 and ≤35 Years of Age
Tidsramme: 2 years after exa-cel infusion
ASCQ-Me is a disease-specific HRQoL questionnaire for adults with sickle cell disease that assesses Emotional Impact, Pain Impact, Social Functioning Impact, Stiffness Impact, Sleep Impact, Pain Episode Frequency, and Pain Episode Severity. Domain scores are reported as T-scores standardized to a reference population where mean = 50, and SD = 10. A change of approximately 5 points (1/2 SD) is considered clinically meaningful. An increase of 5 points indicates improvement for the impact domains, whereas a decrease of 5 points indicates improvement for the Pain Episode Frequency and Pain Episode Severity domains. For impact domain items higher score indicates better HRQoL and lower disease burden. For Pain items lower score indicates a better outcome. Scores are interpreted relative to the reference population mean of 50, taking into account the direction of scoring for each domain.
2 years after exa-cel infusion
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Tidsramme: 2 years after Exa-cel infusion
PedsQL scores were used to assess quality of life of participants. It is a standardized, generic instrument for measuring health related quality of life (HRQoL) in children and adolescents. It includes different domains (Psychosocial health, physical functioning, emotional functioning, social functioning, and school functioning). When completing the PedsQL questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
2 years after Exa-cel infusion
Change in PRO Over Time Assessed Using Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease Module (SCD) for Participants Greater Than or Equal to (≥) 12 and Less Than (<) 18 Years of Age
Tidsramme: 2 years after exa-cel infusion
The PedsQL Sickle Cell Disease Module (PedsQL SCD) is a disease-specific module of the PedsQL. The tool measures self-reported health-related quality of life in participants with SCD across 9 domains: pain and hurt, pain impact, pain management (mgmt), worry I, worry II, emotions, treatment, communication I, and communication II. When completing the PedsQL SCD Module questionnaires, respondents were asked to provide a response on a 5-point scale ranging from 0 (never a problem) to 4 (almost always a problem). Responses were then transformed to a 0 to 100 score, with higher scores reflecting better quality of life.
2 years after exa-cel infusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. november 2018

Primær fullføring (Faktiske)

7. juli 2025

Studiet fullført (Faktiske)

7. juli 2025

Datoer for studieregistrering

Først innsendt

9. november 2018

Først innsendt som oppfylte QC-kriteriene

15. november 2018

Først lagt ut (Faktiske)

19. november 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere